STOCK MARKET TODAY

Oscar Health Stock Forecast 2026 To 2030 : Analysts view on OSCR Stock

US Street Talk News Desk November 30, 2025
4 min read
OSCR Stock Price Forecast
OSCR Stock Price Forecast

New York, 01 December 2025: Oscar Health Inc (OSCR) is a leading American health insurance company that provides technology-based health insurance services. Founded in 2012, the company offers individual and family insurance plans through the Affordable Care Act (ACA) marketplace. Its platform includes AI-based features, telemedicine, and data-driven healthcare solutions, distinguishing it from traditional insurance firms. Listed on the NYSE, OSCR Stock (NYSE: OSCR) are currently trading around $18 (as of November 2025), having registered a 387% increase over the past year.

However, despite reaching a revenue of $3 billion in the recently released Q3 2025 report, net loss has increased. This article will discuss OSCR’s share forecasts from 2026 to 2030, opinions of American analysts, and the company’s positive and negative aspects.

Analysts’ opinion on OSCR stock in the US market

Analysts in the American market view OSCR with a mixed outlook. According to TipRanks, among the ratings given by 5 analysts over the past three months, there is an overall ‘Moderate Sell’ consensus: 1 Buy, 1 Hold and 3 Sell. The average 12-month price target is $16.06, which is 11.56% below the current price. However, there is a positive sentiment due to some key upgrades.

Piper Sandler has recently upgraded OSCR from a ‘Neutral’ to an ‘Overweight’ rating and raised the price target from $13 to $25. This upgrade is based on profitability for 2026 and the extension of ACA subsidies, which will keep enrolment stable. Analysts say that even if the subsidies end, OSCR’s product design and pricing strategy will increase market share and profitability.

On the other hand, institutions like Wells Fargo (Sell, $11), UBS (Sell, $12) and Barclays (Sell, $13) are cautious. According to Yahoo Finance, analysts predict an EPS of -$1.29 (negative) for 2025 and -$0.06 (near break-even) for 2026. Revenue is expected to be $12.02 billion for 2025 and $12.59 billion for 2026. Overall, analysts believe in the path to profitability but remain cautious due to short-term risks.

OSCR Stock Forecast 2026 To 2030

There is significant variability in OSCR’s long-term forecasts, which depends on the company’s growth potential and policy risks. According to various sources, the following estimates are provided:

  • OSCR Stock Forecast 2026: According to Intellect, an average of 23.49 dollars (over 30% increase from current prices). StocksCan is more optimistic at 49.58 dollars (175% increase), high 64.59 dollars. Details on CoinCodex are limited, but 17.47 dollars is expected by 2025.
  • OSCR Stock Forecast 2027: StockScan: $53.77 (199% increase)
  • OSCR Stock Forecast 2028: StockScan: $65.94 (267% increase)
  • OSCR Stock Forecast 2029: StockScan: $82.67 (360% increase)
  • OSCR Stock Forecast 2030: Intellectia: $88.08; StockScan: $99.40 (453% increase); CoinCodex: $17.36 (negative -4% change). Sources like Gov.Capital are bearish, estimating $8.727.

These estimates are based on financial reports, earnings history, and market trends. In an optimistic scenario, tech innovation and ACA expansion could lead to over 400% growth, whereas in a bearish scenario, increased medical costs and subsidy risks could result in stagnation.

OSCR Stock Price Forecast 2026 to 2030

Positive aspects of the Oscar Health Insurance company

Oscar Health has many attractive aspects for investment:

  • Technology-driven innovation: AI-based platforms and new plans (such as menopause-focused insurance) have been launched in markets like South Florida, enhancing customer experience and reducing costs.
  • Strong revenue growth: $3 billion revenue in Q3 2025, with profitability expected by 2026. Adjusted EBITDA of $404 million by 2027.
  • Market expansion: Enrolment will remain stable due to geographic expansion and ACA subsidy extension, resulting in increased market share.
  • Attractive valuation: Being a mid-cap stock trading at low multiples, it has the potential to outperform in 2025 and beyond.
  • Analyst upgrades: Firms like Piper Sandler have given an ‘overweight’ rating, causing the share to rise by 35%.

Negative aspects of the Oscar Health Insurance company

On the other hand, there are some risks associated with OSCR:

  • Rising loss: Net loss of $137.45 million in Q3 2025 (previous year $54.6 million), and EPS -0.53. Nine months loss $90.54 million.
  • Medical cost pressure: Increasing medical expenses have resulted in negative profit margins.
  • Policy risks: Enrolment may decrease if ACA subsidies end, even although OSCR has prepared for it.
  • Moderate sell consensus: The majority of analysts are assigning a sell rating, and the average PT is below.
  • Volatility: The share price fell by 30% last month, even though it has a 387% return in the long term.

Conclusion

Oscar Health (OSCR) is a promising company in the health tech space, which could show significant growth between 2026 and 2030 through innovation and expansion – optimistically, the stock could reach up to $99. While analysts hold mixed views, there is confidence in its path to profitability, particularly with ACA support. However, due to potential losses and policy uncertainties, it remains a risky investment. Investors should make decisions based on their own research and ensure diversification. Keep an eye on future Q4 2025 and 2026 earnings for greater clarity.

Disclaimer: This stock forecast is based on third-party analyses and is for informational purposes only; it does not constitute financial advice or guarantee future performance. Investors should conduct their own research and seek advice from qualified professionals, as market conditions and risks may lead to losses.